Sandoz Group AG

SDZ · SIX

Public Market Listing

SDZSIX

SIX primary exchange listing

Live quotes, historical charts, and market capitalization for Sandoz Group AG are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(9 total)
9Total Assets
9Approved
0Phase 3 / Filed
0Phase 1–2 / Early
17Diseases
Quick filter:
Showing 9 of 9 assets
Target & Modality
Approved
TNF-alphaMonoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid ArthritisHidradenitis SuppurativaNon-Infectious Uveitis
Ulcerative Colitis, Crohn's Disease
Approved
VEGF-AProtein / enzyme therapeutic
Age-Related Macular DegenerationDiabetic Macular Edema
Approved
Beta-2 adrenergic receptorSmall molecule
Asthma
BAT1706(Avzivi)
Approved
VEGF-AMonoclonal antibody
Non-Small Cell Lung CancerOvarian CancerCervical CancerColorectal CancerRenal Cell CarcinomaGlioblastoma
Approved
VEGF-AMonoclonal antibody
Age-Related Macular DegenerationDiabetic Macular Edema
Wet Age-Related Macular Degeneration
Approved
VEGF-AMonoclonal antibody
Age-Related Macular DegenerationDiabetic Macular Edema
Approved
α4 integrinMonoclonal antibody
Multiple Sclerosis
Approved
IL-12 p40Monoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis
Ulcerative Colitis, Crohn's Disease
Approved
Farnesyl pyrophosphate synthase (FPPS)Small molecule
Osteoporosis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$11.1B———report ↗